Enovis Q4 2023 Earnings Report

Enovis EPS Results

• Actual EPS: $0.79
• Consensus EPS: $0.76
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: $0.72

Enovis Revenue Results

• Actual Revenue: $455.00 million
• Expected Revenue: $444.34 million
• Beat/Miss: Beat by +$10.66 million
• YoY Revenue Growth: +11.20%

Enovis Announcement Details

• Quarter: Q4 2023
• Date: 2/22/2024
• Time: Before Market Opens

Enovis (NYSE:ENOV) operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.